NATROX Wound Care

Inotec AMD is a Cambridge-based startup focused on revolutionizing wound care through its innovative Oxygen Wound Therapy. The company has developed a device that produces concentrated oxygen from the surrounding air and delivers it directly to chronic wounds via a thin, flexible tube. Chronic wounds, which are slow to heal, affect millions globally and pose a significant burden on healthcare systems, society, and patients. Inotec AMD aims to address this "silent epidemic" with its FDA-cleared and CE-marked device.

The Oxygen Wound Therapy device is designed to deliver continuous, pure, humidified oxygen to the wound, stimulating the healing process. The system includes a sterile, single-use wound interface that allows the free passage of wound exudate (fluid) into a secondary dressing while optimizing oxygen flow across the wound bed. The device's flexible tube, which is 1 meter long, connects directly to an oxygen generator. The system can remain in place for up to 7 days, depending on clinical needs, and should be changed with each dressing change according to good clinical practice.

Inotec AMD primarily serves wound care specialists and healthcare providers worldwide. The company operates in the medical technology market, focusing on advanced wound care solutions. Its business model involves the sale of its Oxygen Wound Therapy devices to healthcare institutions and professionals, generating revenue through product sales.

The company is backed by Cambridge Capital Group, a leading business angel group, and Cambridge Enterprise Limited, a subsidiary of the University of Cambridge responsible for commercializing university intellectual property. Additionally, Cambridge Angels, a group of high-net-worth investors, support Inotec AMD.

Keywords: chronic wounds, oxygen therapy, wound healing, medical device, healthcare, innovation, Cambridge, FDA-cleared, CE-marked, startup.